Weekly Recap

NeurologyLive Weekly Recap

Each week on Saturday morning, the NeurologyLive^® team puts together a weekly recap that offers a quick look into some of the top headlines in neurology news that you may have missed.

AMX0035 Shows Safety in Alzheimer Disease, Outcomes of Urgent Prevention in TIA, FDA Grants IDE to NeuroPace's RNS System

AMX0035 Shows Safety in Alzheimer Disease, Outcomes of Urgent Prevention in TIA, FDA Grants IDE to NeuroPace's RNS System

NeurologyLive® Staff

November 20th 2021

Neurology News Network for the week ending November 20, 2021.

RBD Shows No Impact Post-DBS, Erenumab Superior to Topiramate, ADORE Phase 3 Trial Begins

RBD Shows No Impact Post-DBS, Erenumab Superior to Topiramate, ADORE Phase 3 Trial Begins

NeurologyLive® Staff

November 13th 2021

Neurology News Network for the week ending November 13, 2021.

Benefits of Physical Activity in PD, Neonatal Seizures Increased During Rewarming, Cluster Headache Characterized by Creaky Voice

Benefits of Physical Activity in PD, Neonatal Seizures Increased During Rewarming, Cluster Headache Characterized by Creaky Voice

NeurologyLive® Staff

November 6th 2021

Neurology News Network for the week ending November 6, 2021.

Ocrelizumab Safety Profile in Elders, Phase 3b CASTING Trial Results, Cannabis Information Sources for MS

NeurologyLive® Staff

October 30th 2021

Neurology News Network for the week ending October 30, 2021.

Cenobamate Provides Long-Term Seizure Reduction, Nerivio's Impact in Chronic Migraine, Weekly Episodes Reduced With FT218

Cenobamate Provides Long-Term Seizure Reduction, Nerivio's Impact in Chronic Migraine, Weekly Episodes Reduced With FT218

NeurologyLive® Staff

October 23rd 2021

Neurology News Network for the week ending October 23, 2021. [WATCH TIME: 3 minutes]

Alemtuzumab Treatment Poplation Identified, Siponimod Preserves Retinal Thickness, ATA188 Shows Success in Phase 1

Alemtuzumab Treatment Poplation Identified, Siponimod Preserves Retinal Thickness, ATA188 Shows Success in Phase 1

NeurologyLive® Staff

October 16th 2021

Neurology News Network for the week ending October 15, 2021. [WATCH TIME: 3 minutes]

XEN1101 Demonstrates Efficacy in Focal Epilepsy, Long-Term Profile of Inebilizumab, Combination of Epilepsy and MS Progress Worse

NeurologyLive® Staff

October 9th 2021

Neurology News Network for the week ending October 9, 2021. [WATCH TIME: 3 minutes]

Study of P2B001 in PD Concludes, Verdiperstat Fails in MSA, Fenfluramine sNDA Submitted for LGS

Study of P2B001 in PD Concludes, Verdiperstat Fails in MSA, Fenfluramine sNDA Submitted for LGS

October 2nd 2021

Neurology News Network for the week of October 2, 2021. [WATCH TIME: 4 minutes]

Noncontact Boxing Improves Movement in Parkinson, Riluzole's Lack of Effect in Spincerebellar Ataxia, Positive Impact of Cannabis in Dystonia

Noncontact Boxing Improves Movement in Parkinson, Riluzole's Lack of Effect in Spincerebellar Ataxia, Positive Impact of Cannabis in Dystonia

NeurologyLive® Staff

September 25th 2021

Neurology News Network for the week ending September 25, 2021. [WATCH TIME: 4 minutes]

AMX0035 NDA Planned, gammaCore Approved to Treat Paroxysmal Hemicrania, Epilepsy Represents Risk Factor for SUD

AMX0035 NDA Planned, gammaCore Approved to Treat Paroxysmal Hemicrania, Epilepsy Represents Risk Factor for SUD

September 18th 2021

Neurology News Network for the week ending September 18, 2021.

Joint Mobilization Exercises Improve Systemic Sclerosis Spasticity, Ocrelizumab Long-Term Safety, Antiplatelets Non-Effect on Recurrent ICH

Joint Mobilization Exercises Improve Systemic Sclerosis Spasticity, Ocrelizumab Long-Term Safety, Antiplatelets Non-Effect on Recurrent ICH

NeurologyLive® Staff

September 11th 2021

Neurology News Network for the week ending September 11, 2021.

Salt Substitutes Reduce Stroke Risk, Access to Rehab Disrupted by COVID-19, Headache Infusion Centers Limited

Salt Substitutes Reduce Stroke Risk, Access to Rehab Disrupted by COVID-19, Headache Infusion Centers Limited

NeurologyLive® Staff

September 4th 2021

Neurology News Network for the week ending September 4, 2021.

Fingolimod Preserves MS Cognition, Ravulizumab ALS Trial Discontinued, ADVANCE Results Published

Fingolimod Preserves MS Cognition, Ravulizumab ALS Trial Discontinued, ADVANCE Results Published

NeurologyLive® Staff

August 28th 2021

Neurology News Network for the week ending August 28, 2021.

ACTH Superior to Treat Infantile Spasms, SESI-HRMS Serves as Viable OSA Screening Tool, Myeloid Microvesicles Diagnostic Value in MS

ACTH Superior to Treat Infantile Spasms, SESI-HRMS Serves as Viable OSA Screening Tool, Myeloid Microvesicles Diagnostic Value in MS

NeurologyLive® Staff

August 21st 2021

Neurology News Network for the week ending August 21, 2021.

DTAS Leads to Improved Stroke Outcomes, FDA Approves Avalglucosidase Alfa, No Evidence of Suicidality in ASMs

DTAS Leads to Improved Stroke Outcomes, FDA Approves Avalglucosidase Alfa, No Evidence of Suicidality in ASMs

NeurologyLive® Staff

August 14th 2021

Neurology News Network for the week ending August 14, 2021.

Seizure Detection Using Machine Learning, Seroconversion Rate Lower in Anti-CD20 Therapies, Age of Diabetes Onset Correlated With Dementia

Seizure Detection Using Machine Learning, Seroconversion Rate Lower in Anti-CD20 Therapies, Age of Diabetes Onset Correlated With Dementia

NeurologyLive® Staff

August 7th 2021

Neurology News Network for the week ending August 7, 2021.

Cenobamate Shows High Retention, Increased Risk of Depression in MS, DAPT Therapy Benefits Moderate Ischemic Stroke

Cenobamate Shows High Retention, Increased Risk of Depression in MS, DAPT Therapy Benefits Moderate Ischemic Stroke

NeurologyLive® Staff

Neurology News Network for the week ending July 24, 2021.

Starstim Device Granted Breakthrough Designation, Natalizumab Reduces Postpartum Relapse Risk, EFRONT Dementia Study Announced

Starstim Device Granted Breakthrough Designation, Natalizumab Reduces Postpartum Relapse Risk, EFRONT Dementia Study Announced

NeurologyLive® Staff

Neurology News Network for the week ending July 17, 2021.

Narcolepsy Severity Scale Shows Benefit, Amantadine Improves Daily Living, Pridopidine's Neuroprotective Properties

Narcolepsy Severity Scale Shows Benefit, Amantadine Improves Daily Living, Pridopidine's Neuroprotective Properties

NeurologyLive® Staff

Neurology News Network for the week ending July 10, 2021.

Lemborexant Shows Positive Medication Effect, New Comparative Study for CGRPs Announced, Ultra-Early Epilepsy Surgery Effective

Lemborexant Shows Positive Medication Effect, New Comparative Study for CGRPs Announced, Ultra-Early Epilepsy Surgery Effective

NeurologyLive® Staff

Neurology News Network for the week ending July 2, 2021.

Eptinezumab Demonstrates Rapid Relief, Zolgensma Improves Motor Function in SMA, RELIEF Study Results

Eptinezumab Demonstrates Rapid Relief, Zolgensma Improves Motor Function in SMA, RELIEF Study Results

NeurologyLive® Staff

Neurology News Network for the week ending June 26, 2021.

Blarcamesine Exceeds Enrollment, Higher Plasma Nusinersen Leads to Meaningful Improvements, Neurodevelopmental Outcomes Unchanged by Maternal ASMs

Blarcamesine Exceeds Enrollment, Higher Plasma Nusinersen Leads to Meaningful Improvements, Neurodevelopmental Outcomes Unchanged by Maternal ASMs

NeurologyLive® Staff

Neurology News Network for the week ending June 19, 2021.

Telemedicine Produces Meaningful Migraine Improvement, Galcanezumab Shows No Wearing Effect, CGRPs All Significant Improve MMDs

Telemedicine Produces Meaningful Migraine Improvement, Galcanezumab Shows No Wearing Effect, CGRPs All Significant Improve MMDs

NeurologyLive® Staff

Neurology News Network for the week ending June 12, 2021.

Experts Call for Better Trial Design, Alzheimer Disease Vaccine Shows Safety, FDA Accepts IND for LION-101

Experts Call for Better Trial Design, Alzheimer Disease Vaccine Shows Safety, FDA Accepts IND for LION-101

NeurologyLive® Staff

Neurology News Network for the week ending June 5, 2021.

ANVS401 Shows Promise in Alzheimer Disease, FDA Approves IND for Ketamine in Parkinson, MedRhythms Collaborates With Massachusetts General Hospital

ANVS401 Shows Promise in Alzheimer Disease, FDA Approves IND for Ketamine in Parkinson, MedRhythms Collaborates With Massachusetts General Hospital

NeurologyLive® Staff

Neurology News Network for the week ending May 29, 2021.

ET Associated With Substantial HCRU, MS Phenotypes Share Common Mechanisms, Hypertension Risk in Menopausal Women With Migraine

ET Associated With Substantial HCRU, MS Phenotypes Share Common Mechanisms, Hypertension Risk in Menopausal Women With Migraine

NeurologyLive® Staff

Neurology News Network for the week ending May 22, 2021.

Gene Therapy in SLC13A5 Deficiency, DMTs Reduce Risk of Disability in Pediatric MS, FASTEST Phase 3 Study Announced

Gene Therapy in SLC13A5 Deficiency, DMTs Reduce Risk of Disability in Pediatric MS, FASTEST Phase 3 Study Announced

NeurologyLive® Staff

Neurology News Network for the week ending May 15, 2021.

VY-HTT01 IND Accepted, SUDEP Associated With Abnormal Cardiac Response, Humoral Response in MS DMTs Identified

VY-HTT01 IND Accepted, SUDEP Associated With Abnormal Cardiac Response, Humoral Response in MS DMTs Identified

NeurologyLive® Staff

Neurology News Network for the week ending May 8, 2021.

Tofersen to Begin Expanded Access, FDA Grants De Novo to Chronic Stroke Rehab Therapy, Brain MRI to Predict Post-Partum Relapses

Tofersen to Begin Expanded Access, FDA Grants De Novo to Chronic Stroke Rehab Therapy, Brain MRI to Predict Post-Partum Relapses

NeurologyLive® Staff

Neurology News Network for the week ending May 1, 2021.

Stroke Common Cause of Seizures, Inebilizumab Demonstrates Continued Benefits, Fremanezumab Safe in Patients With CV Risk

Stroke Common Cause of Seizures, Inebilizumab Demonstrates Continued Benefits, Fremanezumab Safe in Patients With CV Risk

NeurologyLive® Staff

April 24th 2021

Neurology News Network for the week ending April 24, 2021.

<1 2 3 4 5 6 7 8 9 10 >

Do Not Sell My Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.